• About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb®
    • Gloperba®
    • Expanded Access Policy
  • Partners
  • Science
    • Medical information U.S.
    • Publications
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
    • FAQs
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations
Shopping cart close
Scilex Holding Scilex Holding
  • About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb®
    • Gloperba®
    • Expanded Access Policy
  • Partners
  • Science
    • Medical information U.S.
    • Publications
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
    • FAQs
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations

Posts by Jitendra

Home » Articles Posted by Jitendra (Page 14)
03 Jun
SEC FIlings

Prospectuses and communications, business combinations

  • November 17, 2022
  • Posted by Jitendra

Read more

03 Jun
SEC FIlings

Prospectuses and communications, business combinations

  • November 17, 2022
  • Posted by Jitendra

Read more

03 Jun
Press Release

Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes

  • June 2, 2022
  • Posted by Jitendra
PALO ALTO and SAN DIEGO, CA. June 3, 2022 /Newswire/ -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial...

Read more

02 Jun
Press Release

Scilex Holding Company, a Sorrento Company, announces continued growth in ZTlido® in managed health care plans

  • June 2, 2022
  • Posted by Jitendra
Earlier this year, a national pharmacy benefit manager (PBM) moved a large percentage of its patients from not covered to covered, adding access to ZTlido for 5.5 million lives. ZTlido is now...

Read more

27 May
SEC FIlings

Notice of Annual Meeting

  • November 17, 2022
  • Posted by Jitendra

Read more

23 May
SEC FIlings

Prospectuses and communications, business combinations

  • November 17, 2022
  • Posted by Jitendra

Read more

23 May
SEC FIlings

Current report

  • November 17, 2022
  • Posted by Jitendra

Read more

19 May
SEC FIlings

Prospectuses and communications, business combinations

  • November 17, 2022
  • Posted by Jitendra

Read more

18 May
Press Release

Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain

  • May 18, 2022
  • Posted by Jitendra
Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 in subjects with moderate to severe acute lower...

Read more

16 May
SEC FIlings

Quarterly report for quarter ending Mar 31, 2022

  • November 17, 2022
  • Posted by Jitendra

Read more

«‹1213141516›»
Close
Recent Posts
  • scilex-no-pic
    Henry Ji, PhD
    August 21, 2025 No Comments
  • scilex-no-pic
    Stephen Ma
    August 21, 2025 No Comments
  • scilex-no-pic
    Jaisim Shah
    August 21, 2025 No Comments
  • scilex-no-pic
    Dorman Followwill 
    August 21, 2025 No Comments
  • Alexander Wu, PhD
    August 21, 2025 No Comments
scilex-holding-logo-white

Terms of Use  Privacy Policy  Contact

  • Follow us on Facebook
  • Follow us on LinkedIn
  • Contact us by email

©2025 Scilex Holding All Rights Reserved
Scilex Holding Company is the owner of Scilex Pharmaceuticals and Semnur Pharmaceuticals

Scroll To Top Sidebar
We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.
Accept More info